Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph F Gera

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Methods in Enzymology|June 21, 2002
Array-based methods for identifying protein-protein and protein-nucleic acid interactionsJoseph F Gera, Tony R Hazbun, Stanley Fields
Journal of Neuro-Oncology|June 5, 2026
PKA signaling modulates PRMT5/hnRNP A1-mediated IRES translation and dictates responses to mTOR inhibition in glioblastomaSunil Kumar, Angelica Benavides-Serrato, Jacquelyn T Saunders, et al.
Molecular Cancer Therapeutics|January 28, 2022
Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple MyelomaYijiang Shi, Fumou Sun, Yan Cheng, et al.
Cancer Research|December 17, 2008
IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1Yijiang Shi, Patrick J Frost, Bao Q Hoang, et al.
Molecular Cancer Therapeutics|August 7, 2012
A cell-penetrating bispecific antibody for therapeutic regulation of intracellular targetsRichard H Weisbart, Joseph F Gera, Grace Chan, et al.
The Journal of Biological Chemistry|October 25, 2003
AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expressionJoseph F Gera, Ingo K Mellinghoff, Yijiang Shi, et al.
Molecular Cancer Therapeutics|August 10, 2019
A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor CytotoxicityMario I Vega, Yijiang Shi, Patrick Frost, et al.
Cancer Discovery|December 7, 2011
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistanceKazuhiro Tanaka, Ivan Babic, David Nathanson, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Methods in Enzymology|June 21, 2002
Array-based methods for identifying protein-protein and protein-nucleic acid interactionsJoseph F Gera, Tony R Hazbun, Stanley Fields
Journal of Neuro-Oncology|June 5, 2026
PKA signaling modulates PRMT5/hnRNP A1-mediated IRES translation and dictates responses to mTOR inhibition in glioblastomaSunil Kumar, Angelica Benavides-Serrato, Jacquelyn T Saunders, et al.
Molecular Cancer Therapeutics|January 28, 2022
Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple MyelomaYijiang Shi, Fumou Sun, Yan Cheng, et al.
Cancer Research|December 17, 2008
IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1Yijiang Shi, Patrick J Frost, Bao Q Hoang, et al.
Molecular Cancer Therapeutics|August 7, 2012
A cell-penetrating bispecific antibody for therapeutic regulation of intracellular targetsRichard H Weisbart, Joseph F Gera, Grace Chan, et al.
The Journal of Biological Chemistry|October 25, 2003
AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expressionJoseph F Gera, Ingo K Mellinghoff, Yijiang Shi, et al.
Molecular Cancer Therapeutics|August 10, 2019
A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor CytotoxicityMario I Vega, Yijiang Shi, Patrick Frost, et al.
Cancer Discovery|December 7, 2011
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistanceKazuhiro Tanaka, Ivan Babic, David Nathanson, et al.
Pageof 1